ESR1 Data Fuel Novel Breast Cancer Strategies
OncLive,
Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine…
Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine…
Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for…
- The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
SOURCE Agendia, Inc. - The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early…
Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and…
Irvine, CA, USA and Amsterdam, the Netherlands, May 15, 2018 / B3C newswire / -- Agendia, Inc., a world leader in personalized…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
SOURCE Agendia, Inc. - Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of…
/PRNewswire/ --., a world leader in personalized medicine and molecular cancer diagnostics, announced that Aetna, Cigna and…
IRVINE, Calif. and AMSTERDAM, May 1, 2018 /PRNewswire/ -- Agendia, Inc., a world leader in personalized medicine and molecular…
Politik Donnerstag, 21. Dezember 2017 /jarun011, stock.adobe.com Kln Wissenschaftler des Instituts fr Qualitt und…
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Joint…
Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical…
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Joint…
Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical…
By The ASCO Post Posted: 7/11/2017 3:25:57 PM Last Updated: 7/11/2017 3:25:57 PM Tweet this page Advertisement New…
July 11, 2017 The American Society of Clinical Oncology updated its guidelines to include the 70-gene MammaPrint assay to…
In an update to its 2016 clinical practice guideline on the use of biomarkers in early invasive breast cancer, the American…
IRVINE, Calif.
ASCO recommends MammaPrint ® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform…
Women who have clinically high-risk, hormone receptor (HR)-positive, HER2-negative breast cancer may use results of the…
] Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Society…
IRVINE, Calif.
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Society of…
IRVINE, Calif.
IRVINE, Calif.
ASCO recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions…
] Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the 15 th St.
IRVINE, Calif.
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the 15th St.
IRVINE, Calif.
IRVINE, Calif.
IRVINE, Calif.